Health Affairs, 25, no. 5 (2006): 1281-1290 doi: 10.1377/hlthaff.25.5.1281 © 2006 by Project HOPE	New Online   New Issue: China & India   Obesity In China   Pay Cuts For Medicare Docs   Access To Care Woes

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Garrison, L. P. Articles by Austin, M.J. F. Search for Related Content PubMed PubMed Citation Articles by Garrison, L. P., Jr. Articles by Austin, M.J. F. Related Collections Insurance Market Access To Care Business Of Health Consumer Issues Evidence-Based Medicine Insurance Coverage International Issues Pharmaceuticals Research And Technology Health Spending

Evolution & Future

Linking Pharmacogenetics-Based Diagnostics And Drugs For Personalized Medicine

Progress toward personalized medicine in the five years following the sequencing of the human genome has been slower than many expected. We focus on two potential factors that might be important in explaining this disappointing progress: the limitations of genetic prediction and the lack of appropriate economic incentives. Clinical application of DNA-based and other biomarkers is likely to succeed only on a case-by-case basis, depending on such factors as information content of the biomarker, accuracy of current assessment methods, and effectiveness of available interventions. Both strong intellectual property and value-based, flexible pricing systems will be important in making personalized medicine a reality.

                      What's this?